Study of Copanlisib in Hepatic or Renal Impairment

Phase 1

Completed

• Conditions: Hepatic Insufficiency, Renal Insufficiency
• Interventions: Drug: Copanlisib (ALIQOPA, BAY80-6946)

• Registration Number: NCT03172884
• Lead Sponsor: Bayer

Brief Summary

To evaluate the pharmacokinetics and safety of copanlisib in subjects with impaired hepatic or renal function in comparison to healthy subjects

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2017-05-30
• Study First Submitted QC: 2017-05-31
• Study First Posted: 2017-06-01
• Study Start: 2017-06-14
• Primary Completion: 2020-03-13
• Study Completion: 2020-05-15
• Results First Submitted: 2021-03-10
• Results First Submitted QC: 2021-03-10
• Status Verified: 2021-04
• Results First Posted: 2021-04-01
• Last Update Submitted: 2021-04-06
• Last Update Posted: 2021-04-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

All subjects - Male and female subjects between 18 and 80 years of age with a body mass index above 18.0 and below 34.0 kg / m² and a body weight of above or equal 50 kg.

Healthy subjects

• Healthy subjects as determined by absence of clinically significant deviation from normal in medical history, physical examination, vital signs, electrocardiograms, and clinical laboratory determinations. eGFR ≥ 90 mL/min/1.73 m² (according to Modification of Diet in Renal Disease [MDRD] formula).

Subjects with moderate or severe hepatic impairment

• Subjects with confirmed liver cirrhosis by at least one of the following Criteria: histologically by prior liver biopsy showing cirrhosis, liver imaging (computer tomography, and/or ultrasound and/or magnetic resonance imaging scans, and/or fibroscan), or laparoscopy.
• Child-Pugh Clinical Assessment Score 7 to 9 (moderate) or Score 10 to 15 (severe).

Subjects with severe renal impairment

• Subjects with severe renal impairment with an estimated glomerular filtration rate 15-29 mL/min/1.73 m² according to MDRD formula.
• Subjects with stable renal disease: no significant change in renal function as evidenced by serum creatinine value within ±25% from the last determination, obtained within at least 3 months before study entry and the absence of the need to start dialysis in the next 3 months.

Read More

Exclusion Criteria

All subjects

• Active coronary artery disease or myocardial infarction within 6 months of study entry. Immuno-compromised subjects including known history/seropositivity of human immunodeficiency virus (HIV).
• Other concurrent severe and/or uncontrolled medical conditions (e.g. current diagnosis of type 1 or type 2 diabetes mellitus and with HbA1c >8.5%) that could cause unacceptable safety risks or compromise compliance with protocol.
• Previous or concurrent history of malignancies within 5 years prior to study treatment except for curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial bladder cancer as well as localized prostate cancer.
• Uncontrolled hypertension despite optimal medical management (per investigator's assessment).
• Administration of strong CYP3A4 inhibitors or inducers within 2 weeks prior to dosing and during study conduct. (A list of these medications can be found in Section 16.6 of the protocol. However, this list may not be comprehensive).

Subjects with moderate or severe hepatic impairment

• Symptoms or history of encephalopathy (Grade III or worse)
• Failure of any other major organ other than the liver; severe infection, or any clinically significant illness within 4 weeks prior to study drug administration
• Renal failure with an eGFR <35 mL/min/1.73 m² Subjects with severe renal impairment
• Acute renal failure at study entry
• Nephrotic syndrome
• Failure of any other major organ other than the kidney
• Acute hepatorenal syndrome

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BAY80-6946/severe renal impaired patients	Copanlisib (ALIQOPA, BAY80-6946)	Patients with eGFR 15-29 mL/min/1.73 m\^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation
BAY80-6946/severe hepatically impaired patients	Copanlisib (ALIQOPA, BAY80-6946)	Patients with Child-Pugh C (score 10-15) at the screening visit
BAY80-6946/Healthy subject	Copanlisib (ALIQOPA, BAY80-6946)	Healthy subjects
BAY80-6946/moderate hepatically impaired patients	Copanlisib (ALIQOPA, BAY80-6946)	Patients with Child-Pugh B (score 7-9) at the screening visit

Primary Outcome Measures

Name	Time	Method
Maximum Observed Concentration (Cmax) of Copanlisib in Plasma.	before copanlisib administration as well as 10 min and 1 h (end of infusion), 1.5, 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120 and 168 h after start of infusion	Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
Area Under the Concentration vs. Time Curve From Zero to Infinity (AUC) of Copanlisib in Plasma.	before copanlisib administration as well as 10 min and 1 h (end of infusion), 1.5, 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120 and 168 h after start of infusion	AUC refers to area under the concentration vs time curve from 0 to infinity which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
Area Under the Concentration-time Curve of Copanlisib in Plasma Over the Time Interval From 0 to 168 h.	before copanlisib administration as well as 10 min and 1 h (end of infusion), 1.5, 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120 and 168 h after start of infusion	AUC(0-168) refers to AUC from time 0 to 168 hr which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.

Secondary Outcome Measures

Name	Time	Method
Number of Subjects With Treatment-emergent Adverse Events (TEAEs) in Different Severity.	Up to 30 days after end of treatment with study drug	Adverse events are considered to be treatment-emergent if they have started or worsened after first application of study medication up to 30 days after end of treatment with study medication.
Number of Subjects With Treatment-emergent Adverse Events (TEAEs)	Up to 30 days after end of treatment with study drug	Adverse events are considered to be treatment-emergent if they have started or worsened after first application of study medication up to 30 days after end of treatment with study medication.
Maximum Observed Concentration (Cmax) of Metabolite M-1.	before copanlisib administration as well as 10 min and 1 h (end of infusion), 1.5, 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120 and 168 h after start of infusion	The morpholinone derivative M-1 is a minor copanlisib metabolite in plasma. The PK of metabolite M-1 is routinely analyzed in addition to the PK of the parent compound, although M-1 is not considered to be a major metabolite. Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
Area Under the Concentration-time Curve of Metabolite M-1 in Plasma Over the Time Interval From 0 to 168 h.	before copanlisib administration as well as 10 min and 1 h (end of infusion), 1.5, 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120 and 168 h after start of infusion	The morpholinone derivative M-1 is a minor copanlisib metabolite in plasma. The PK of metabolite M-1 is routinely analyzed in addition to the PK of the parent compound, although M-1 is not considered to be a major metabolite. AUC from time 0 to 168h which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.

Trial Locations

Locations (2)

Institutul National de Boli Infectioase Prof.Dr.Matei Bals; 🇷🇴 Bucuresti, Romania

CRS Clinical-Research-Services Kiel GmbH; 🇩🇪 Kiel, Schleswig-Holstein, Germany